Clínica Baviera, S.A. (BME:CBAV)

Clínica Baviera Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	45.95	42.06	40.21	35.97	29.52	27.39
Depreciation & Amortization	24.19	22.13	19.98	16.46	14.8	13.89
Other Amortization	1.76	1.76	0.9	0.52	0.2	0.2
Asset Writedown & Restructuring Costs	0.1	0.1	-0.03	0.03	0.47	0.03
Loss (Gain) From Sale of Investments	-0.37	-0.37	-1.22	-	-	-
Provision & Write-off of Bad Debts	0.18	0.18	0.06	-0.02	0.18	0.06
Other Operating Activities	1.95	2.69	4.41	3.09	3.25	1.44
Change in Accounts Receivable	0.28	0.28	0.22	-0.43	0.18	-0.91
Change in Inventory	-0.04	-0.04	-0.25	-0.31	-0.23	-0.29
Change in Accounts Payable	8.05	8.05	-1.78	2.5	5.02	5.04
Operating Cash Flow	77.15	76.84	62.51	57.81	53.38	46.86
Operating Cash Flow Growth	15.56%	22.93%	8.12%	8.31%	13.92%	48.96%

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-30.83	-30.01	-26.51	-22.68	-14.03	-10.58
Cash Acquisitions	0	-0.92	-11.11	-	-	-0.05
Divestitures	20.34	20.34	30.58	-	-	-
Investment in Securities	-29.12	-35.95	-14.16	-21.79	1.4	-6.46
Other Investing Activities	1.49	1.52	0.3	0.15	0.07	0
Investing Cash Flow	-38.12	-45.02	-20.9	-44.31	-12.56	-17.08

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Long-Term Debt Issued	-	3	7.2	-	-	0.08
Long-Term Debt Repaid	-	-12.86	-11.79	-10.52	-13.69	-13.43
Net Debt Issued (Repaid)	-10.02	-9.86	-4.59	-10.52	-13.69	-13.35
Issuance of Common Stock	5.51	3.16	1.43	0.71	0.6	0.5
Repurchase of Common Stock	-5.01	-2.39	-10.24	-0.71	-0.62	-0.49
Common Dividends Paid	-24.27	-25.13	-25.09	-13.04	-16.79	-17.15
Other Financing Activities	-3.54	-2.24	-1.17	-0.81	-0.95	-0.31
Financing Cash Flow	-37.34	-36.45	-39.66	-24.37	-31.45	-30.8

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	-0.04	0.08	-0.12	-	-	-
Net Cash Flow	1.66	-4.55	1.83	-10.87	9.37	-1.02

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	46.32	46.83	36	35.13	39.35	36.28
Free Cash Flow Growth	10.67%	30.08%	2.46%	-10.71%	8.45%	53.50%
Free Cash Flow Margin	14.45%	15.36%	13.55%	15.47%	19.83%	20.94%
Free Cash Flow Per Share	2.89	2.92	2.25	2.15	2.41	2.23
Levered Free Cash Flow	42.44	40.45	30.98	26.81	33.33	31.68
Unlevered Free Cash Flow	44.08	41.88	31.74	27.16	33.59	31.96

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	0.97	0.69	0.18	0.11	0.46	0.11
Cash Income Tax Paid	17.97	17.33	13.08	11.64	9.63	11.28
Change in Working Capital	3.39	8.29	-1.81	1.76	4.96	3.84

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 25, 2026

Data Sources Report a data error